Jun. 19 at 8:22 AM
$SANA do you know in what you have invested - this company seeks for DT1 cure and yet you all comment daily price movements? I have DT1 child and I know every aspect of disease, treatment, options, possibilities - SANA has unique treatment and most probably has a cure, no one else has it - there is no placebo here so if injection worked at one patient with partially modified cells, it is a huge probability that it will work to all others with fully modified derived cells. We will know that over the next 12 months as they will start P1 soon. If they have a cure, this is 50bn company, unless M&A arrives (which is unfortunately a risk not a benefit). So the strategy here should be, invest some money and forget about it - forget about broad market, dilutions, headlines, till they say "P1 showed gene editing worked and patients were cured". P1 will be enough for a conclusion.
